What Patients and Societies Really Think About Million-Dollar Gene Therapies

Gene therapies have moved from laboratory promise to clinical reality, and with that transition has come an uncomfortable question that science alone cannot answer: what are these treatments actually worth, and who gets to decide? A new research article published in Gene Therapy examines the values, perceptions and preferences of patients, consumers and broader society regarding high-cost gene therapies, an area of medicine where a single infusion can carry a price tag in the millions of dollars. By gathering evidence on how the people who ultimately fund, receive and live with these therapies think about them, the work addresses one of the most consequential gaps in the conversation surrounding advanced therapeutic products.

The technical achievements behind gene therapy are genuine and, in several cases, spectacular.Vectors derived from adeno-associated virus, lentiviral ex vivo modification of hematopoietic stem cells, and CRISPR-based editing approaches have produced durable, sometimes curative responses in conditions that previously demanded lifelong management. Hemophilia, spinal muscular atrophy, inherited retinal disease, beta-thalassemia and sickle cell disease all now have licensed gene-based treatments in major markets. Yet each approval has been shadowed by cost figures that strain the conventional logic of pharmaceutical pricing, with list prices frequently ranging from roughly one million to more than three million dollars per patient. These prices reflect real development costs, small target populations, complex manufacturing and the framing of a therapy as a one-time cure rather than a recurring prescription.

What has often been missing from the pricing debate is a systematic account of patient and public preference. Health technology assessment bodies typically rely on cost-effectiveness modeling, quality-adjusted life year thresholds and budget impact analyses. Those instruments are essential, but they compress human experience into parameters. The newly published analysis takes a different angle, synthesizing what is known about how patients weigh the uncertain durability of a one-time therapy against established treatments, how much value people place on freedom from lifelong monitoring and adherence burdens, and how perceptions of risk shift when a therapy is novel and its long-term effects cannot yet be fully characterized.

Uncertainty sits at the heart of the patient perspective. Gene therapies delivered today have follow-up horizons measured in years, while their intended benefit spans decades or a lifetime. Patients considering such treatments must confront questions that clinical trials cannot fully resolve: will expression or editing persist, will delayed adverse events emerge, and if the effect wanes, can the therapy be repeated or rescued by conventional care? Surveys and preference studies in this literature consistently show that willingness to accept a one-time intervention depends heavily on disease severity, the availability of alternatives, the age at which treatment can occur, and the degree to uncertainty is communicated honestly by clinicians and manufacturers. Patients are not uniformly risk-averse or risk-seeking; their choices track the specifics of their condition and circumstances.

Societal preferences add another dimension that is easy to overlook in clinical discussions. When the public pays for therapies through insurance pools, national health services or government programs, the affordability of one patient’s cure becomes intertwined with access for others. Research on public values in healthcare financing suggests broad support for funding genuinely transformative treatments, but also concern about opportunity costs, about paying premium prices for uncertain long-term benefit, and about equity when eligibility depends on where a patient lives or how their health system reimburses. High-cost gene therapies sharpen these tensions because their budget impact is concentrated and front-loaded: a small number of patients treated in a single year can consume resources that would otherwise serve many others with less dramatic but well-established interventions.

The article also engages with the emerging contractual and financial mechanisms designed to reconcile these tensions. Outcome-based payment agreements, installment models, annuity payments tied to continued benefit, and money-back guarantees have all been piloted as ways to share risk between payers and manufacturers. Patient and consumer preferences matter here in practical ways. Patients and families may value the certainty of upfront payment structures differently than payers do; they may worry about the consequences of losing coverage if a payment-for-performance contract ends; and they may have strong views about who bears the administrative and monitoring burden that these schemes create. Evidence on preferences can inform whether such mechanisms are designed in ways that patients actually find acceptable and trustworthy.

Another recurring theme in the values literature is trust. Gene therapy arrived after decades of overpromising, from the early enthusiasm of the 1990s through tragic setbacks such as the death of Jesse Gelsinger and the leukemias linked to early retroviral vectors. Rebuilding confidence required both technical improvement and transparent communication. The perception studies summarized in the new article indicate that trust in regulators, clinicians and manufacturers shapes acceptance as much as the scientific data do. Communities that have experienced historical inequities in medical research, including Black and Indigenous communities disproportionately affected by conditions such as sickle cell disease, bring justified skepticism that must be addressed through genuine engagement rather than marketing. Preference research that captures these community perspectives provides an evidence base for engagement that goes beyond consultation theater.

Access equity emerges as perhaps the most charged issue. The countries and health systems with the greatest capacity to pay are typically the first to reimburse gene therapies, while the global burden of many target conditions, including sickle cell disease, falls heavily on low- and middle-income countries. Public preferences collected in high-income settings cannot simply be exported; values research increasingly emphasizes the need to understand priorities in the communities where therapies could deliver the largest health gains. There are also intergenerational and distributive questions: should a health system pay three million dollars to cure one infant now, or deploy that budget across prevention, screening and supportive care programs whose collective benefit may be larger? The article’s synthesis of societal perceptions shows that the public is capable of reasoning about these trade-offs and generally expects decision-makers to do so openly.

Methodologically, the research landscape the article surveys includes discrete choice experiments, contingent valuation studies, deliberative public engagement panels, qualitative interview studies and preference surveys of patients and caregivers. Each method has strengths and limits. Discrete choice experiments quantify trade-offs between attributes such as durability, risk, administration burden and price. Deliberative panels surface the reasoning behind preferences and can accommodate value pluralism. Qualitative work captures the lived texture of decisions that surveys flatten. Bringing these strands together, as the article does, offers a more complete picture than any single study, and it highlights persistent gaps: few studies capture preferences in low-resource settings, few follow patients after treatment to see whether anticipated preferences matched lived experience, and few examine how preferences evolve as real-world effectiveness data accumulate.

The policy implications are clear even where the answers remain contested. Pricing decisions for gene therapies should be informed by documented patient and public values, not only by cost-effectiveness arithmetic. Risk-sharing contracts should be evaluated against patient acceptability, not merely payer savings. Communication about uncertainty should be a regulatory and clinical obligation rather than a courtesy. And equity in global access should be treated as a design constraint for the next generation of therapies rather than an afterthought. As more gene and cell therapies approach approval, including potential one-time treatments for far more common conditions such as cardiovascular and neurodegenerative disease, the affordability questions raised by today’s ultra-rare-disease products will scale dramatically. Understanding what patients, consumers and societies actually value, and building health systems that respect those values, is no longer optional. It is the condition on which the gene therapy revolution will be judged, in the clinic and at the ballot box alike.

Subject of Research: Patient, consumer and societal values, perceptions and preferences regarding high-cost gene therapies

Article Title: Patient, consumer and societal values, perceptions and preferences on high-cost gene therapies

Article References: Rush, A., Gomez, M., Pierce, K., Richard, D. A. L., Mason, K., Howard, K., Lynch, G., Walker, P., Viney, R., & Watson, J. (2026). Patient, consumer and societal values, perceptions and preferences on high-cost gene therapies. Gene Therapy. https://doi.org/10.1038/s41434-026-00643-z

Image Credits: AI Generated

DOI: 10.1038/s41434-026-00643-z

Keywords: gene therapy, high-cost therapies, patient preferences, societal values, health technology assessment, outcome-based payment, access equity, health economics, uncertainty, public trust, rare diseases, pricing